Navigation Links
Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
Date:6/16/2013

yclics entered into a collaboration and license agreement in December 2011 to co-develop and co-commercialize ibrutinib. The regulatory filing for ibrutinib in MCL is expected to be made prior to the end of the third quarter of 2013. Details about the complete ibrutinib clinical program is posted on clinicaltrials.gov.

To date, ibrutinib has been granted three Breakthrough Therapy Designations by the U.S. Food & Drug Administration (FDA) as a monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with deletion of the short arm of chromosome 17 (del17p); patients with relapsed/refractory MCL who have received prior therapy, and in patients with Waldenstrom's macroglobulinemia (WM). The implications of Breakthrough Therapy Designation cannot be determined at this time.

About B-Cell Malignancies
Both MCL and DLBCL are part of a family of blood cancers which originate from malignant B-cells. Unlike healthy B-cells, malignant B-cells ignore signals to die and continue to develop and reproduce in the lymph.[1][2][3] When a malignancy is described as 'relapsed', it means that it has returned after an initial partial or total remission.[4] 'Refractory' refers to cancer that has become resistant to current treatment.[5]

About Janssen Research & Development, LLC
At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world. Janssen Research & D
'/>"/>

SOURCE Janssen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
2. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
3. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
4. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
5. Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from U.S. Food and Drug Administration
6. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
7. Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
8. Ibrutinib Expanded Access Program Open to Eligible U.S. Patients with Relapsed or Refractory Mantle Cell Lymphoma
9. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , September 30, 2014 ... report the "Glycobiology/Glycomics Market by Product [Enzymes (Glycosyltransferase, ... Kits, and Reagents], Application (Immunology, Oncology) & ... 2019", published by MarketsandMarkets, provides a detailed ... opportunities, current market trends, and strategies impacting ...
(Date:9/30/2014)... 30, 2014   Easy Breathe , the fastest ... announced that it now offers the revolutionary AirSense ... the first sleep apnea therapy devices with internal cellular ... to track and share real-time data on each user,s ... CPAP therapy.  In addition, the internal modem allows the ...
(Date:9/30/2014)... 30, 2014 The Chinese wound care market ... rise in the incidence of lifestyle diseases, coupled with ... affordability of better quality of wound care products provide ... coverage of public health insurance schemes and increased reimbursement ... Based on the findings of primary and secondary researches, ...
Breaking Medicine Technology:Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4China Wound Care Market 2China Wound Care Market 3
... today announced that it has received approval from the U.S. Food & Drug Administration to market Alprazolam orally disintegrating tablets. Distribution of the product will commence immediately.   , ... ... ... ...
... Inc. (Nasdaq: MITI ) announced today the closing of its previously announced underwritten public offering. Prior to closing, the ... sold a total of 11.5 million shares of its common stock at a public offering price of $7.00 ... ... , , ...
Cached Medicine Technology:Actavis Receives Approval of Alprazolam ODT in the U.S. 2Actavis Receives Approval of Alprazolam ODT in the U.S. 3Micromet Closes $80.5 Million Public Offering of Common Stock 2Micromet Closes $80.5 Million Public Offering of Common Stock 3Micromet Closes $80.5 Million Public Offering of Common Stock 4
(Date:10/1/2014)... Lifeinsurance-policy.com has released a new blog post explaining ... smokers. , Smoking will always have a negative impact ... best method to find affordable coverage. Insurance brokerage websites ... , Whole life insurance premiums will be fixed ... coverage is permanent, the initial rates are very ...
(Date:10/1/2014)... 01, 2014 Join the more than 80 ... Treatment Center’s first ever charity golf tournament to benefit Project ... eating disorders who cannot afford treatment. The tournament will be ... Eureka, Mo. , The day-long event starts with 10:30 ... and award dinner will begin at 5 p.m. and will ...
(Date:10/1/2014)... 01, 2014 Diet Doc understands that many ... lose weight and their dieting attempts could be easily sabotaged ... hormone diet treatments into their programs as a ... see fast and effective weight loss results, it also allows ... habits to maintain their weight for the future. , Earlier ...
(Date:10/1/2014)... occasion of the Leishmaniasis East Africa Platform meeting, ... leishmaniasis experts, results of a pharmacovigilance or ... carried out by MSF, DNDi, and national partners ... to key decision makers in order to boost ... combination of Sodium Stibogluconate and Paromomycin (SSG&PM) in ...
(Date:10/1/2014)... Today marks the final day prosthodontist Dr. ... Oxnard and Woodland Hills, Calif., is in the southern ... , “Speaking to this group of specialists allows more ... the help and care they deserve,” Dr. Jivraj said. ... work, providing cosmetic dentistry, correcting bite issues, placing implants, ...
Breaking Medicine News(10 mins):Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4Health News:Results of large-scale roll out of combination treatment for kala-azar in Eastern Africa 2Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 2Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 3Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 4Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 5
... ... Facebook group regarding the McNeil Consumer Healthcare recall have drafted a downloadable ... Senators. This letter details unanswered questions of concerned parents as McNeil ... of children,s and infant,s Tylenol, Motrn, Zyrtec and Benadryl. This letter ...
... ... Office-LinX 7.1 Recognized for Exceptional Innovation, , ... Richmond Hill, ON (PRWEB) May 7, 2010 ... 7.1 as a recipient of its 2009 Unified Communications magazine Product of the ...
... , ... Healthcare professionals informed of every milestone leading to regulatory approval for,Alair® and Provenge®, ... ... and consulting company, announces the release of two reports on first-of-a-kind technologies just ...
... of Assisted Living Facilities (ALFs) in Los Angeles showed that ... was associated with declining quality of life and increased depression ... published today in the Journal of the American Geriatrics ... they are unable to live independently, but do not require ...
... risk by up to 40 percent, researchers say , THURSDAY, ... role triglyceride levels might play in heart disease, and finally ... fat to an increased risk of heart trouble. , ... disease prevention efforts, but experts say a new report ...
... National Institutes of Health (NIH) has awarded a $2.7-million ... project with Case Western Reserve University School of Nursing, ... Medical Center in Cleveland to study cognitive impairment in ... Heart, Lung, And Blood Institute runs through Jan. 31, ...
Cached Medicine News:Health News:Facebook Group for McNeil Product Recall Organizes Letter Writing Campaign – Urges Concerned Parents to Contact House of Representatives and Senators 2Health News:Esna Technologies Receives Unified Communications Magazine's 2009 Product of the Year Award 2Health News:Esna Technologies Receives Unified Communications Magazine's 2009 Product of the Year Award 3Health News:Esna Technologies Receives Unified Communications Magazine's 2009 Product of the Year Award 4Health News:Hayes, Inc. Technology Prognosis Team Tracks First-of-a-Kind Technologies 2Health News:Older people in assisted-living facilities sleep poorly 2Health News:Genes Tie Blood Fat to Heart Disease 2Health News:Genes Tie Blood Fat to Heart Disease 3Health News:NIH awards $2.7-million grant to Kent State to study cognitive impairment in heart failure patients 2Health News:NIH awards $2.7-million grant to Kent State to study cognitive impairment in heart failure patients 3
... objective and high power negative lens delivering ... true benefit of this system is ease ... is made possible due to a superior ... bar and individual interpupillary adjustment provides stability ...
23 gauge thin wall irrigation. 25 gauge thin wall aspiration. Angled 30 degree shaft 8 mm from tip to bend. Irrigation tip set 0.5 mm behind aspiration tip. Dual hub construction. Polished finish. Ov...
This specially designed 23 gauge spoon-shaped cannula is connected to a balanced salt solution bottle and with a low-flow of fluid, is designed to allow a controlled cleaning of the stromal interface...
... five legs for extra stability. Adjustable height ... travel 6"). 2" ball bearing swivel hard ... upholstery, available in black vinyl as standard, ... a contoured, padded, upholstered backrest, with vertical ...
Medicine Products: